GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Valuation Rank
中文

Spero Therapeutics (STU:2HA) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Spero Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Valuation Rank
Comparable Companies
VANI ELTX KZR ATHA KNTE CRVS ANEB SABS ACET TSBX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
SPRO:USA
Address
675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139
Website
https://www.sperotherapeutics.com
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.